GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Longevity Health Holdings Inc (NAS:XAGE) » Definitions » Research & Development

XAGE (Longevity Health Holdings) Research & Development : $1.05 Mil (TTM As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Longevity Health Holdings Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Longevity Health Holdings's Research & Development for the three months ended in Dec. 2024 was $0.19 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 was $1.05 Mil.

Longevity Health Holdings Research & Development Historical Data

The historical data trend for Longevity Health Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Longevity Health Holdings Research & Development Chart

Longevity Health Holdings Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Research & Development
0.98 2.20 2.50 1.05

Longevity Health Holdings Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.66 0.43 0.10 0.33 0.19

Longevity Health Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Longevity Health Holdings  (NAS:XAGE) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Longevity Health Holdings Research & Development Related Terms

Thank you for viewing the detailed overview of Longevity Health Holdings's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Longevity Health Holdings Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Longevity Health Holdings Inc (NAS:XAGE) » Definitions » Research & Development
Comparable Companies
TANH PURE SKVI SNBH DQWS PG XPAR:OR LSE:ULVR CL BOM:500696 KVUE KMB LSE:RKT XTER:HEN3 XTER:BEI CHD EL TSE:4452 OSTO:ESSITY B CLX
Traded in Other Exchanges
N/A
Address
2403 Sidney Street, Suite 300, Pittsburgh, PA, USA, 15203
Website
https://www.carmellcorp.com
Longevity Health Holdings Inc is a United States based bio-aesthetics company focused on developing, manufacturing, and marketing cosmetic skincare and haircare products. The company has two cosmetic product lines, Carmell Secretome and Elevai Exosomes, that support skin and hair health.
Executives
Richard A Upton director 12 MIDDLE STREET, AMHERST NH 03031
Kathryn Gregory director 305 THAYER POND ROAD, WILTON CT 06897
Patrick A Sturgeon officer: CFO and Secretary 600 LEXINGTON AVENUE 33 FLOOR, NEW YORK NY 10022
David W Anderson director 519 LYNMERE ROAD, BRYN MAWR PA 19010
Rajiv Shukla director, 10 percent owner, officer: Chief Executive Officer EMERALD VIEW SUITE 400, 2054 VISTA PARKWAY, WEST PALM BEACH FL 33411
Randolph W Hubbell director, officer: President and CEO C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
William R Newlin director C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
Steven Bariahtaris director C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
Jaime Garza director C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
Janet Vargo officer: VP Clinical Services C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
Donna Godward officer: Chief Quality Officer C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
James C Hart officer: Chief Medical Officer C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
William Woodward director ANTHEM VENTURE PARTNERS, 225 ARIZONA AVENUE, SUITE 200, SANTA MONICA CA 90401
Darlene T Deremer director 200 CENTRAL AVENUE, SUITE 1850, ST. PETERSBURG FL 33701
Ahac Sponsor Iii Llc 10 percent owner 1177 AVENUE OF THE AMERICAS, 5TH FLOOR, NEW YORK NY 10036